Recursion Pharmaceuticals, Inc. (RXRX)
3.04
-0.18
(-5.59%)
USD |
NASDAQ |
Jun 10, 16:00
3.11
+0.07
(+2.30%)
Pre-Market: 08:04
Recursion Pharmaceuticals SG&A Expense (Quarterly) : 34.59M for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 34.59M |
| December 31, 2025 | 33.66M |
| September 30, 2025 | 41.63M |
| June 30, 2025 | 46.65M |
| March 31, 2025 | 54.65M |
| December 31, 2024 | 77.19M |
| September 30, 2024 | 37.76M |
| June 30, 2024 | 31.83M |
| March 31, 2024 | 31.41M |
| December 31, 2023 | 30.46M |
| September 30, 2023 | 29.20M |
| June 30, 2023 | 28.29M |
| March 31, 2023 | 22.87M |
| Date | Value |
|---|---|
| December 31, 2022 | 19.84M |
| September 30, 2022 | 19.49M |
| June 30, 2022 | 21.20M |
| March 31, 2022 | 21.07M |
| December 31, 2021 | 19.20M |
| September 30, 2021 | 15.69M |
| June 30, 2021 | 13.85M |
| March 31, 2021 | 8.937M |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 6.964M |
| June 30, 2020 | 5.159M |
| March 31, 2020 | 5.561M |
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Stoke Therapeutics, Inc. | 19.97M |
| Agenus, Inc. | 6.86M |
| Amgen, Inc. | 1.602B |
| BioCryst Pharmaceuticals, Inc. | 94.55M |
| Imunon, Inc. | 1.969M |